Fig. 7

A2AR blockade enhances the anti-tumor response of CD8⁺ T cells in HNSCC mouse model. a Dot plots of A2AR⁺ CD8⁺ T cells in spleen from vehicle group and SCH58261 group (left). Quantification of the percentage of A2AR⁺CD8⁺ T cells in spleen, lymph node, peripheral blood and tumor was displayed with bar graph (right, each group n = 6, Mean ± SEM, **, P < 0.01, ***, P < 0.001, unpaired t test). b Representative photos of CD8 immunohistochemical staining in the tumor from vehicle group or SCH58261 group were shown (scale bar = 100 μm)). The histoscore of CD8 of each group were calculated and presented with bar graph (each group n = 6, Mean ± SEM, ***, P < 0.001, t test). c Quantifications of the population of CD8⁺ T cells in spleen, lymph node, peripheral blood and tumor from WT mice, Vehicle group and SCH58261 group (each group n = 6, Mean ± SEM, *, P < 0.05, **, P < 0.01, unpaired t test). d Dot plots of IFN-γ⁺ CD8⁺ T cells in tumor infiltrating lymphocytes (TILs) from vehicle group and SCH58261 group (left). Quantification of the percentage of IFN-γ⁺ CD8⁺ T was displayed with bar graph (right, each group n = 6, Mean ± SEM, **, P < 0.01, unpaired t test). e Production of IFN-γ and TNF-α of the CD8⁺ T cells from SCH58261 treated 2cKO tumor bearing mice was significantly increased as compared with the mice from vehicle group (each group n = 6, Mean ± SEM, *, P < 0.05, **, P < 0.01, unpaired t test)